Establishment of a noninvasive diagnostic model for chronic hepatitis B liver fibrosis patients with normal aminotransferases aged ≤30 years

Qingrong TANG; Changxiang LAI; Fang WANG; Jin LU; Chunhua XU; Xiangjun LI; Yizhou XU

doi:10.12449/JCH240912

Volume 40 Issue 9

Sep. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(9): 1790-1795

PDF( 831 KB)

Establishment of a noninvasive diagnostic model for chronic hepatitis B liver fibrosis patients with normal aminotransferases aged ≤30 years

DOI: 10.12449/JCH240912

Qingrong TANG¹,
Changxiang LAI²,
Fang WANG^{2
,
,
,},
Jin LU^{1
,
,
,},
Chunhua XU¹,
Xiangjun LI¹,
Yizhou XU¹

1.
Department of Infectious Diseases，The First Hospital of Changsha，Changsha 410000，China
2.
Second Department of Liver Diseases，Shenzhen Third People’s Hospital，Shenzhen，Guangdong 518112，China

Research funding:

Key Discipline Construction Project of Shenzhen (SZXK076)

More Information

Corresponding author: WANG Fang， 807874297@qq.com （ORCID： 0009-0003-0092-3403）; LU Jin， 2276984@qq.com （ORCID： 0000-0003-0035-1890）
Received Date: 2024-01-29
Accepted Date: 2024-03-18
Published Date: 2024-09-25

Abstract

Abstract

Objective To establish a noninvasive diagnostic model for liver fibrosis in chronic hepatitis B （CHB） patients with normal alanine aminotransferase （ALT） and an age of ≤30 years by selecting specific indicators from the commonly used noninvasive indicators such as clinical， biochemical， and imaging indicators， to avoid invasive liver biopsy in such patients to some extent， and to guide the timing of antiviral therapy. Methods A total of 251 CHB patients with normal ALT and an age of ≤30 years who underwent liver biopsy in Shenzhen Third People’s Hospital and The First Hospital of Changsha from January 2019 to January 2022 were enrolled， with 175 patients in the model group and 76 patients in the validation group， and commonly used clinical indicators were obtained based on clinical experience and related articles. The two-independent-samples t test or the two-independent-samples Mann-Whitney U rank sum test was used for comparison of continuous data between groups， and the chi-square test was used for comparison of categorical data between groups. A Spearman rank correlation analysis was used to investigate the correlation between each indicator and liver fibrosis and identify the indicators with correlation （P<0.01， r>0.200）； a Logistic regression analysis was used to establish a noninvasive diagnostic model， and the receiver operating characteristic （ROC） curve was used to evaluate its performance and perform validation of the model； this model was then compared with the widely used models of aspartate aminotransferase-to-platelet ratio index （APRI） and fibrosis-4 （FIB-4）. The Kappa consistency test was used to investigate the consistency of pathological results. Results A total of 17 commonly used clinical indicators were obtained， among which 9 indicators （ALT， aspartate aminotransferase ［AST］， gamma-glutamyl transpeptidase ［GGT］， ferritin ［FERR］， platelet count ［PLT］， procollagen type Ⅲ amino-terminal peptide ［PⅢP］， collagen Ⅳ ［CⅣ］， HBV DNA， and spleen thickness） were correlated with liver fibrosis （P<0.01， r>0.232）. Based on the above indicators， the predictive model was established as P=1/（1+e^-γ）， γ=-1.902+0.106×AST－0.011×PLT－0.265×HBV DNA+0.059×PⅢP， in which P was the probability for predicting ≥S2 liver fibrosis and γ was the predictive index. The comparison between each indicator and the model showed that the model had the largest area under the ROC curve of 0.852， with a sensitivity of 92.7% and a specificity of 76.9%. The model was validated in 76 patients and showed an accuracy of 77.600%. The model was compared with APRI and FIB-4， and the results showed that the model has good accuracy. Conclusion Compared with the models of APRI and FIB-4 commonly used in the world， this model can more accurately judge the degree of liver fibrosis in such patients， thereby replacing liver biopsy to some extent and guiding the timing of antiviral therapy.
- Age Groups,
- Hepatitis B， Chronic,
- Transaminases,
- Diagnosis

FullText(HTML)

References(21)

References

[1]	Hepatology Branch of Chinese Medical Association, Infectious Diseases Branch of Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
[2]	SONNEVELD MJ, BROUWER WP, CHAN HL, et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: Results from the SONIC-B study[J]. Lancet Gastroenterol Hepatol, 2019, 4( 7): 538- 544. DOI: 10.1016/S2468-1253(19)30087-1.
[3]	ZHOU XL, WANG YB, LU W, et al. Value of five noninvasive serum models in the diagnosis of chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2021, 37( 7): 1567- 1571. DOI: 10.3969/j.issn.1001-5256.2021.07.018. 周新兰, 王雁冰, 陆伟, 等. 5种血清无创模型对慢性乙型肝炎肝纤维化分期诊断价值的比较[J]. 临床肝胆病杂志, 2021, 37( 7): 1567- 1571. DOI: 10.3969/j.issn.1001-5256.2021.07.018.
[4]	FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48( 2): 335- 352. DOI: 10.1016/j.jhep.2007.11.011.
[5]	WU XJ, WANG Y, CHEN J, et al. Baseline predictors of virological response for chronic hepatitis B patients[J]. World J Gastroenterol, 2009, 15( 34): 4311- 4315. DOI: 10.3748/wjg.15.4311.
[6]	CAO W, CHEN HD, YU YW, et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134( 7): 783- 791. DOI: 10.1097/CM9.0000000000001474.
[7]	LIU J, ZHANG SK, WANG QM, et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China: A population-based, cross-sectional study[J]. Lancet Infect Dis, 2016, 16( 1): 80- 86. DOI: 10.1016/S1473-3099(15)00218-2.
[8]	LUO X, QU Y, CAI XB, et al. Effects of antiviral therapy on the reversal of liver fibrosis[J]. J Clin Hepatol, 2022, 38( 11): 2596- 2598. DOI: 10.3969/j.issn.1001-5256.2022.11.032. 罗昕, 曲颖, 蔡晓波, 等. 抗病毒治疗对肝纤维化逆转的影响[J]. 临床肝胆病杂志, 2022, 38( 11): 2596- 2598. DOI: 10.3969/j.issn.1001-5256.2022.11.032.
[9]	MIAO L, JIA CH, CHEN HD, et al. Study on the factors influencing the reversal of liver fibrosis after the treatment of chronic hepatitis B with Entecavir received virological response[J]. Clin J Med Offic, 2024, 52( 2): 176- 179. DOI: 10.16680/j.1671-3826.2024.02.17. 苗亮, 贾春辉, 陈寒冬, 等. 恩替卡韦治疗慢性乙型肝炎获得病毒学应答后肝纤维化逆转影响因素研究[J]. 临床军医杂志, 2024, 52( 2): 176- 179. DOI: 10.16680/j.1671-3826.2024.02.17.
[10]	LIU YN, LI MW, WANG LJ, et al. HBeAg-negative chronic HBV-infected individuals with normal alanine aminotransferase and an age of ≤30 years should be taken seriously when expanding anti-HBV treatment for chronic hepatitis B[J]. J Clin Hepatol, 2022, 38( 7): 1477- 1481. DOI: 10.3969/j.issn.1001-5256.2022.07.006. 刘燕娜, 李明蔚, 王雷婕, 等. 扩大慢性乙型肝炎抗病毒治疗应重视ALT正常、年龄≤30岁的HBeAg阴性慢性HBV感染者[J]. 临床肝胆病杂志, 2022, 38( 7): 1477- 1481. DOI: 10.3969/j.issn.1001-5256.2022.07.006.
[11]	JURY TE. Easl international consensus conference on hepatitis B[J]. J Hepatol, 2003, 39( S1): 3- 25.
[12]	LOK A. Chronic hepatitis B[J]. Hepatology, 2001, 34( 6): 1225- 1241. DOI: 10.1053/jhep.2001.29401.
[13]	NONG CL, LONG TH, GUO Q. Characteristics of liver histology and the correlated index in patients with chronic hepatitis B and normal ALT levels[J]. J Pract Med, 2012, 28( 9): 1447- 1449. DOI: 10.3969/j.issn.1006-5725.2012.09.020. 农村立, 龙腾河, 郭堑. ALT正常的慢性乙型肝炎肝组织学特点相关性无创指标分析[J]. 实用医学杂志, 2012, 28( 9): 1447- 1449. DOI: 10.3969/j.issn.1006-5725.2012.09.020.
[14]	YANG Q, LIU HE, YOU J, et al. Noninvasive diagnostic models for chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2021, 37( 10): 2420- 2424. DOI: 10.3969/j.issn.1001-5256.2021.10.034. 杨琴, 刘怀鄂, 游晶, 等. 慢性乙型肝炎肝纤维化的无创诊断模型[J]. 临床肝胆病杂志, 2021, 37( 10): 2420- 2424. DOI: 10.3969/j.issn.1001-5256.2021.10.034.
[15]	WEN Y, QU ZY, LU JN, et al. Value of liver-muscle signal intensity and serum markers in diagnosis of chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2023, 39( 3): 573- 579. DOI: 10.3969/j.issn.1001-5256.2023.03.014. 温雅, 屈兆宇, 鲁景楠, 等. 肝肌信号强度比及血清标志物对慢性乙型肝炎肝纤维化的诊断价值[J]. 临床肝胆病杂志, 2023, 39( 3): 573- 579. DOI: 10.3969/j.issn.1001-5256.2023.03.014.
[16]	LEE MH, CHEONG JY, UM SH, et al. Comparison of surrogate serum markers and transient elastography(fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis[J]. Dig Dis Sci, 2010, 55( 12): 3552- 3560. DOI: 10.1007/s10620-010-1219-0.
[17]	ADINOLFI LE, GIORDANO MG, ANDREANA A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis[J]. Br J Haematol, 2001, 113( 3): 590- 595. DOI: 10.1046/j.1365-2141.2001.02824.x.
[18]	CHEN YC, HSU CW, JENG WJ, et al. Advanced liver fibrosis is associated with necroinflammatory grade but not hepatic steatosis in chronic hepatitis B patients[J]. Dig Dis Sci, 2021, 66( 12): 4492- 4500. DOI: 10.1007/s10620-020-06761-x.
[19]	DENG Y, ZHANG S, JI D. Research progress on low-level viremia in chronic hepatitis B[J]. Infect Dis Inf, 2021, 34( 4): 342- 346. DOI: 10.3969/j.issn.1007-8134.2021.04.014. 邓亚, 张珊, 纪冬. 慢性乙型肝炎低水平病毒血症的研究进展[J]. 传染病信息, 2021, 34( 4): 342- 346. DOI: 10.3969/j.issn.1007-8134.2021.04.014.
[20]	LI YD, FAN RS. Analysis of indications for antiviral therapy in chronic HBV patients with persistent normal level of alanine aminotransferase[J/CD]. Electron J Emerg Infect Dis, 2023, 8( 1): 44- 47. DOI: 10.19871/j.cnki.xfcrbzz.2023.01.009. 李延东, 范荣山. 谷丙转氨酶持续正常的慢性乙型肝炎病毒感染者肝脏病理特征及预测因素[J/CD]. 新发传染病电子杂志, 2023, 8( 1): 44- 47. DOI: 10.19871/j.cnki.xfcrbzz.2023.01.009.
[21]	ZHENG M, CAI WM, WENG HL, et al. ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis[J]. Chin J Infect Dis, 2002, 20( 4): 225- 228. DOI: 10.3760/j.issn: 1000-6680.2002.04.009. 郑敏, 蔡卫民, 翁红雷, 等. ROC曲线评价血清纤维化指标对诊断肝纤维化的价值[J]. 中华传染病杂志, 2002, 20( 4): 225- 228. DOI: 10.3760/j.issn:1000-6680.2002.04.009.

Relative Articles

[1]	Xinyu CUI, Yanyan LI, Na ZHU, Yingying LIN, Xin LI. Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2024, 40(3): 489-495. doi: 10.12449/JCH240309
[2]	Gongqin QIU, Dan XIE, Ziren CHEN, Shi OUYANG. Significance of high-sensitivity polymerase chain reaction in detecting hepatitis B virus in chronic hepatitis B patients with a very low viral load[J]. Journal of Clinical Hepatology, 2024, 40(3): 483-488. doi: 10.12449/JCH240308
[3]	Xiaowei AI, Mengyang ZHANG, Yameng SUN, Hong YOU. Key recommendations in guidelines for the prevention， diagnosis， care and treatment for people with chronic hepatitis B infection released by the World Health Organization in 2024[J]. Journal of Clinical Hepatology, 2024, 40(5): 928-933. doi: 10.12449/JCH240510
[4]	Hui ZHUANG. Progress towards elimination of hepatitis B[J]. Journal of Clinical Hepatology, 2024, 40(5): 857-860. doi: 10.12449/JCH240501
[5]	Jingnan LU, Yansong LI, Ya WEN, Xionghui WANG, Zhaoyu QU, Jianlong LI, Wei ZHANG. Application value of liver/spleen CT value， controlled attenuation parameter， and magnetic resonance imaging-proton density fat fraction in chronic hepatitis B patients with hepatic steatosis[J]. Journal of Clinical Hepatology, 2024, 40(1): 46-51. doi: 10.12449/JCH240109
[6]	Xinyu DU, Jia LI, Bei JIANG, Kunyu ZHAO, Yue HU, Fengmei WANG, Fengmin LU. Noninvasive diagnostic indicators for histologically defined immune tolerance state in patients with chronic HBV infection and establishment and assessment of related models[J]. Journal of Clinical Hepatology, 2024, 40(12): 2392-2398. doi: 10.12449/JCH241208
[7]	Meng REN, Junxiu TAO, Ziming LI, Qi HAO, Yi YANG, Yufeng SHI, Yifan LIU, Yue XU, Tongtong ZHENG, Xiaodong LI. Influencing factors for compliance with hepatocellular carcinoma surveillance in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(9): 2096-2102. doi: 10.3969/j.issn.1001-5256.2023.09.010
[8]	Xiaobin LI, Bowen LIU, Feng LI, Xiaopeng SU, Shiping HU. Theory and practice of immunoregulatory therapy with traditional Chinese medicine for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(12): 2908-2913. doi: 10.3969/j.issn.1001-5256.2023.12.023
[9]	Baisheng HUANG, Lanxin OU, Yingjie ZHANG, Meijie SHI, Sheng LI, Huanming XIAO, Xiaoling CHI. Value of traditional noninvasive fibrosis models in diagnosis of significant liver fibrosis in patients with chronic hepatitis B and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(9): 2110-2116. doi: 10.3969/j.issn.1001-5256.2023.09.012
[10]	Yuan WANG, Huaie LIU, Jie DING, Qingqing WANG, Aili WANG, Hui SUN, Hui CAO. Role of new serological markers in evaluating the progression of liver disease in patients with chronic HBV infection and normal aminotransferases[J]. Journal of Clinical Hepatology, 2023, 39(3): 644-650. doi: 10.3969/j.issn.1001-5256.2023.03.026
[11]	Mingli HU, Qixia WANG, Xiong MA. Considerations on the elevation of aminotransferases in primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2021, 37(10): 2277-2279. doi: 10.3969/j.issn.1001-5256.2021.10.005
[12]	Xu ZhiQiang, Dong Yi, Wang FuChuan, Wang LiMin, Yan JianGuo, Cao LiLi, Wang Pu, Li AiQin, Zhong YanWei, Zhang Min. Value of transient elastography in the diagnosis of liver fibrosis in chronic hepatitis B children of different ages[J]. Journal of Clinical Hepatology, 2020, 36(6): 1268-1272. doi: 10.3969/j.issn.1001-5256.2020.06.016
[13]	Wang Lu, Han Ying. An excerpt of British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis (2019)[J]. Journal of Clinical Hepatology, 2019, 35(9): 1937-1941. doi: 10.3969/j.issn.1001-5256.2019.09.010
[14]	Chang Yue, Zhang Wen, Liu QinYu, Zhang Qing, Chen Kai, Li Hai. Effect of silibinin on liver aminotransferases in patients with nonalcoholic fatty liver disease: A meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(5): 1057-1060. doi: 10.3969/j.issn.1001-5256.2019.05.024
[15]	Zhao Qi, Wang Bing, Li ZhenFang, Fang ChunFang, Li Cong, Li SenLin. Clinical significance of abnormal liver function in determining the etiology and severity of acute pancreatitis[J]. Journal of Clinical Hepatology, 2018, 34(1): 152-156. doi: 10.3969/j.issn.1001-5256.2018.01.031
[16]	Ke YeFang, Gao GuoSheng, Zhu Zhe, Chen BiCheng. Value of serum adenosine deaminase in diagnosis of marked liver fibrosis in patients with chronic hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2018, 34(4): 760-763. doi: 10.3969/j.issn.1001-5256.2018.04.013
[17]	Guo Jing, Sun Mei. Diagnosis and differential diagnosis of diseases with elevated aminotransferase in children[J]. Journal of Clinical Hepatology, 2015, 31(8): 1230-1234. doi: 10.3969/j.issn.1001-5256.2015.08.012
[18]	Gao Chun, Fang Long, Yao ShuKun. Correlation of GGT with AFP and diagnostic value of GGT for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 921-925. doi: 10.3969/j.issn.1001-5256.2014.09.021
[19]	Shang DanHe, Chen YanPing, Li ChunYan. The research in liver tissue pathology of chronic HBV infection patients[J]. Journal of Clinical Hepatology, 2013, 29(11): 874-877. doi: 10.3969/j.issn.1001-5256.2013.11.018
[20]	Li YanLi, Zhao Yan, Zhao DanTong, Zhang HaiPing, Sun LiMei, Ma YinXue, Hu WenJing, Yan HuiPing. Age-related clinical features of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2013, 29(2): 146-149.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(6)

Get Citation

PDF

XML

Article Metrics

Article views (348) PDF downloads(32)

Establishment of a noninvasive diagnostic model for chronic hepatitis B liver fibrosis patients with normal aminotransferases aged ≤30 years

DOI: 10.12449/JCH240912

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Establishment of a noninvasive diagnostic model for chronic hepatitis B liver fibrosis patients with normal aminotransferases aged ≤30 years

DOI: 10.12449/JCH240912

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content